Last reviewed · How we verify
Progesterone-IBSA Injectable Solution
Progesterone binds to progesterone receptors in the uterus and other reproductive tissues to maintain pregnancy and regulate the menstrual cycle.
Progesterone binds to progesterone receptors in the uterus and other reproductive tissues to maintain pregnancy and regulate the menstrual cycle. Used for Luteal phase support in assisted reproductive technology (ART), Threatened or recurrent miscarriage prevention.
At a glance
| Generic name | Progesterone-IBSA Injectable Solution |
|---|---|
| Also known as | Prolutex |
| Sponsor | IBSA Institut Biochimique SA |
| Drug class | Progestin |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics/Gynecology |
| Phase | Phase 3 |
Mechanism of action
Progesterone is a naturally occurring steroid hormone that acts as a ligand for intracellular progesterone receptors (PR-A and PR-B). Upon binding, it modulates gene transcription to promote endometrial secretion, suppress uterine contractions, and maintain the corpus luteum, thereby supporting early pregnancy maintenance and preventing miscarriage.
Approved indications
- Luteal phase support in assisted reproductive technology (ART)
- Threatened or recurrent miscarriage prevention
Common side effects
- Injection site pain or irritation
- Headache
- Breast tenderness
- Mood changes
- Abdominal discomfort
Key clinical trials
- Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer. (PHASE3)
- Comparison of the Effect of Subcutaneous Progesterone and Vaginal Progesterone for Luteal Phase Support (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: